SEC Filing Summary: Spherix Incorporated (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2007, for Spherix Incorporated. The Company operates two principal segments: InfoSpherix, which provides contact center and reservation services (primarily for government entities), and BioSpherix, which develops proprietary biotechnology products, specifically focusing on "Naturlose" (tagatose) for Type 2 diabetes treatment. As of April 2007, the Company signed a non-binding letter of intent to sell the InfoSpherix subsidiary to focus exclusively on BioSpherix.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Revenue | $5,347,172 | $5,922,164 |
| Net Loss | $(2,290,521) | $(533,029) |
| Loss Per Share (Basic/Diluted) | $(0.16) | $(0.04) |
| Cash and Cash Equivalents | $9,882,630 | $4,459,530 |
| Working Capital | $9.5 million | $10.9 million (Dec 31, 2006) |
| Operating Cash Flow | $(1,540,689) | $(455,960) |
| Debt | $0 (Bank line of credit) | $0 (Bank line of credit) |
Note: The filing text does not provide a specific gross margin percentage, but gross margin dollars were $431,000 for Q1 2007 compared to $998,000 for Q1 2006.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 9.7% ($575,000) compared to Q1 2006. This was primarily due to the conclusion of the National Park Service contract on January 23, 2007, which had contributed $794,000 in revenue in the prior year's first quarter.
- Increased R&D Expenses: Research and development expenses surged to $1,399,603 in Q1 2007 from $104,751 in Q1 2006. This increase is attributed to the planning and initiation of a Phase 3 clinical trial for Naturlose.
- Widened Net Loss: The net loss expanded significantly to $2.29 million from $533,000, driven by the loss of the NPS contract revenue and the substantial increase in R&D costs.
- Interest Income: Interest income increased to $109,995 from $34,246, resulting from higher cash balances invested following a $6 million settlement award received in October 2006.
Guidance, Outlook, and Risks
- Strategic Shift: The Company intends to sell the InfoSpherix subsidiary (expected to close by summer 2007) to fund the BioSpherix division. Proceeds from the sale and existing cash reserves are intended to finance the Phase 3 clinical trial.
- Capital Requirements: Management expects to expend up to $5 million over the next year on R&D costs related to the Phase 3 trial. The trial is expected to take at least two years to complete.
- Contingencies: The sale of InfoSpherix is subject to contingencies, including the execution of a definitive agreement and stockholder approval. If the sale does not close, the Company may need to reassess the continuation of the clinical trials due to increased costs.
- Risks: Key risks include the failure of the Phase 3 trial, the inability to secure pharmaceutical partners, and the adverse financial impact of losing the National Park Service contract.
Investor Verification Checklist
- Verify the status and terms of the non-binding letter of intent to sell the InfoSpherix subsidiary.
- Confirm the timeline and enrollment progress of the Phase 3 clinical trial for Naturlose (Type 2 diabetes).
- Monitor cash burn rate relative to the projected $5 million R&D expenditure for the upcoming year.
- Review the impact of the lost National Park Service contract on future InfoSpherix revenue streams pending the sale.
- Check for updates on the $10.2 million Federal net operating loss carryforwards and their utilization potential.